Raquel Izumi

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Combination Therapy

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Melanie M Frigault, Arushi Mithal, Harvey Wong, Beatrix Stelte-Ludwig, Vinay Mandava, Xin Huang, Joseph Birkett, Amy J Johnson, Raquel Izumi, Ahmed M Hamdy
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer research communications (2023)
Jennifer R Diamond, Valentina Boni, Emerson A Lim, Grzegorz Nowakowski, Raul Cordoba, Daniel Morillo, Ray Valencia, Isabelle Genvresse, Claudia Merz, Oliver Boix, Melanie M Frigault, Joy M Greer, Ahmed M Hamdy, Xin Huang, Raquel Izumi, Harvey Wong, Victor Moreno
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (7) (2022)
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, Philip Lienau, Gerhard Siemeister, Karsten Denner, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Ulf Bömer, Martina Schäfer, Stuart Ince, Dominik Mumberg, Arne Scholz, Raquel Izumi, Stuart Hwang, Franz von Nussbaum
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. Journal of medicinal chemistry 64 (15) (2021)